Search Results - "Olotu, Fisayo A"

Dynamic perspectives into the mechanisms of mutation‐induced p53‐DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy by Olotu, Fisayo. A., Soliman, Mahmoud E. S.

“…The DNA‐binding ability of p53 represents the crux of its tumor suppressive activities, which involves transcriptional activation of target genes responsible…”
Get full text

Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries by Jing, Lanlan, Wu, Gaochan, Hao, Xia, Olotu, Fisayo A., Kang, Dongwei, Chen, Chin Ho, Lee, Kuo-Hsiung, Soliman, Mahmoud E.S., Liu, Xinyong, Song, Yuning, Zhan, Peng

“…Cell division cycle 25 (Cdc25) protein phosphatases play key roles in the transition between the cell cycle phases and their association with various cancers…”
Get full text

Probing the Highly Disparate Dual Inhibitory Mechanisms of Novel Quinazoline Derivatives against Mycobacterium tuberculosis Protein Kinases A and B by Olotu, Fisayo A, Soliman, Mahmoud E

“…( ) serine/threonine (Ser/Thr) Protein kinases A (PknA) and B (PknB) have been identified as highly attractive targets for overcoming drug resistant…”
Get full text

Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus by Olotu, Fisayo A, Soliman, Mahmoud E S

“…The ongoing search for viable treatment options to curtail Epstein Barr Virus (EBV) pathogenicity has necessitated a paradigmatic shift towards the design of…”
Get full text

Integrative immunoinformatics paradigm for predicting potential B-cell and T-cell epitopes as viable candidates for subunit vaccine design against COVID-19 virulence by Sarma, Vyshnavie R, Olotu, Fisayo A, Soliman, Mahmoud E S

“…BACKGROUNDThe increase in global mortality rates from SARS-COV2 (COVID-19) infection has been alarming thereby necessitating the continual search for viable…”
Get full text

Tweaking α -Galactoceramides: Probing the Dynamical Mechanisms of Improved Recognition for Invariant Natural Killer T-cell Receptor in Cancer Immunotherapeutics by Washah, Houda, Agoni, Clement, Olotu, Fisayo A, Munsamy, Geraldene, Soliman, Mahmoud E S

“…The last few decades have witnessed groundbreaking research geared towards immune surveillance mechanisms and have yielded significant improvements in the…”
Get more information

Covalent Inhibition in Drug Discovery: Filling the Void in Literature by Bjij, Imane, Olotu, Fisayo A, Agoni, Clement, Adeniji, Emmanuel, Khan, Shama, El Rashedy, Ahmed, Cherqaoui, Driss, Soliman, Mahmoud E S

“…The serendipitous discovery of covalent inhibitors and their characteristic potency of inducing irreversible and complete inhibition in therapeutic targets…”
Get more information

In Silico Repurposing of J147 for Neonatal Encephalopathy Treatment: Exploring Molecular Mechanisms of Mutant Mitochondrial ATP Synthase by Emmanuel, Iwuchukwu A, Olotu, Fisayo A, Agoni, Clement, Soliman, Mahmoud E S

“…Neonatal Encephalopathy (NE) is a mitochondrial ATP synthase (mATPase) disease, which results in the death of infants. The case presented here is reportedly…”
Get more information

Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain by Olotu, Fisayo A., Omolabi, Kehinde F., Soliman, Mahmoud E.S.

“…The systematic entry of SARS-CoV-2 into host cells, as mediated by its Spike (S) protein, is highly essential for pathogenicity in humans. Hence, targeting the…”
Get full text

Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful? by Aljoundi, Aimen K, Agoni, Clement, Olotu, Fisayo A, Soliman, Mahmoud E S

“…Amidst the numerous effective therapeutic options available for the treatment of Diffuse Large B-cell Lymphoma (DLBCL), about 30-40% of patients treated with…”
Get more information

Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer by Akinsiku, Oluwayimika E, Soremekun, Opeyemi S, Olotu, Fisayo A, Soliman, Mahmoud E S

“…The selective targeting of CREB-cAMP-responsive element-binding protein (CBP) has recently evolved as a vital therapeutic approach for curtailing its aberrant…”
Get more information

Does Size Really Matter? Probing the Efficacy of Structural Reduction in the Optimization of Bioderived Compounds – A Computational “Proof-of-Concept” by Olotu, Fisayo A., Munsamy, Geraldene, Soliman, Mahmoud E.S.

“…Over the years, numerous synthetic approaches have been utilized in drug design to improve the pharmacological properties of naturally derived compounds and…”
Get full text

Alcohol Metabolic Inefficiency: Structural Characterization of Polymorphism-Induced ALDH2 Dysfunctionality and Allosteric Site Identification for Design of Potential Wildtype Reactivators by Adeniji, Emmanuel A., Olotu, Fisayo A., Soliman, Mahmoud E. S.

“…Liver mitochondrial aldehyde dehydrogenase 2 (ALDH2) enzyme is responsible for the rapid conversion of acetaldehyde to acetic acid. ALDH2 (E487K) polymorphism…”
Get full text

Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex by Olotu, Fisayo A., Omolabi, Kehinde F., Soliman, Mahmoud E. S.

Get full text

Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say? by Agoni, Clement, Olotu, Fisayo A., Ramharack, Pritika, Soliman, Mahmoud E.

“…The drug discovery process typically involves target identification and design of suitable drug molecules against these targets. Despite decades of…”
Get full text

From mutational inactivation to aberrant gain‐of‐function: Unraveling the structural basis of mutant p53 oncogenic transition by Olotu, Fisayo A., Soliman, Mahmoud E.S.

“…Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream…”
Get full text

Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins by Olotu, Fisayo A., Agoni, Clement, Adeniji, Emmanuel, Abdullahi, Maryam, Soliman, Mahmoud E.

“…Selective inhibition is a key focus in the design of chemotherapeutic compounds that can abrogate the oncogenic activities of anti-apoptotic Bcl-2 proteins…”
Get full text

Solving the riddle: Unraveling the mechanisms of blocking the binding of leukotoxin by therapeutic antagonists in periodontal diseases by Abdullahi, Maryam, Olotu, Fisayo A., Soliman, Mahmoud E.

“…Aggregatibacter actinomycetemcomitans is a Gram‐negative bacteria that has gained wide recognition for its causative role in the development of various immune…”
Get full text

Across the blood-brain barrier: Neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer's disease using bioinformatics and computational tools by Lawal, Maryam, Olotu, Fisayo A., Soliman, Mahmoud E.S.

“…The discovery and developmental processes of CNS drugs have been limited by the inability of potential drug molecules to pass through the blood-brain barrier…”
Get full text

Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1-4 by Olotu, Fisayo A., Soliman, Mahmoud E. S.

“…The specific inhibition of aberrant Fibroblast Growth Factor Receptors (FGFRs) has been identified as a feasible strategy to therapeutically ameliorate their…”
Get full text